News
Applicants for the short proposal that submitted their proposal before 10 AM on the 30 th January , have received their results on the 9th March.
Applicants for the short proposal that have submitted after 10 AM on the 30 th January, will not receive their results in time to apply for the 13th March cut off, and can apply for the 3rd October cut off.
Source - EISMEA
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
The network of National Contact Points (NCPs) for the European Research Council (ERC), mERCury, has recently published the first edition of the ERC Success Stories from Widening countries. The collection features seven ERC grantees from Malta, Croatia, Romania, Slovenia, Latvia, Greece and Türkiye who have received Starting, Consolidator,...
Read moreThe selected projects of the 2026 European Research Council (ERC) Synergy Grant call (call deadline 5 November 2025) were published by the ERC Executive Agency. Synergy grant projects consist of minimum two to maximum four researchers or Principal Investigators (PIs) and their teams that jointly address ambitious research problems that could...
Read moreThe new European Partnership for Resilient Cultural Heritage (RCH) that kicked off at the end of September has launched its first Joint Transnational Call (JTC): "Foundations for climate-resilient cultural heritage: Assessing and managing impact and risk, dealing with damage and loss". This first call within the RCH Partnership invites research...
Read moreNCP_WIDERA.NET, the WIDERA National Contact Points network, has so far put six projects, funded under the ERA part of the Horizon Europe WIDERA or Horizon 2020 Science with and for Society (Swafs) work programmes, in the spotlight in their ERA Success Stories series. The latest project example is COALESCE Advancing Leadership and Engagement in...
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
